Compound ID | 2877
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Indirect acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Inhibits class A, C, and some D beta-lactamases |
| Target Pathogen: | Active against carbapenemase-producing Enterobacteriaceae |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound |
| Institute where first reported: | QiLu Pharmaceutical |
| Year first mentioned: | 2023 |
| Highest development stage: | Phase 2 (NCT05060419) |
| Development status: | Active as of 2024 |